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Abstract
NPRL2, one of the tumor suppressor genes residing in a 120-kb homozygous deletion region of human chromosome band
3p21.3, has a high degree of amino acid sequence homology with the nitrogen permease regulator 2 (NPR2) yeast gene,
and mutations of NPRL2 in yeast cells are associated with resistance to cisplatin-mediated cell killing. Previously, we showed
that restoration of NPRL2 in NPRL2-negative and cisplatin-resistant cells resensitize lung cancer cells to cisplatin treatment in
vitro and in vivo. In this study, we show that sensitization of non-small cell lung cancer (NSCLC) cells to cisplatin by NPRL2 is
accomplished through the regulation of key components in the DNA-damage checkpoint pathway. NPRL2 can
phosphorylate ataxia telangiectasia mutated (ATM) kinase activated by cisplatin and promote downstream c-H2AX
formation in vitro and in vivo, which occurs during apoptosis concurrently with the initial appearance of high-molecular-
weight DNA fragments. Moreover, this combination treatment results in higher Chk1 and Chk2 kinase activity than does
treatment with cisplatin alone and can activate Chk2 in pleural metastases tumor xenograft in mice. Activated Chk1 and
Chk2 increase the expression of cell cycle checkpoint proteins, including Cdc25A and Cdc25C, leading to higher levels of G2/
M arrest in tumor cells treated with NPRL2 and cisplatin than in tumor cells treated with cisplatin only. Our results therefore
suggest that ectopic expression of NPRL2 activates the DNA damage checkpoint pathway in cisplatin-resistant and NPRL2-
negative cells; hence, the combination of NPRL2 and cisplatin can resensitize cisplatin nonresponders to cisplatin treatment
through the activation of the DNA damage checkpoint pathway, leading to cell arrest in the G2/M phase and induction of
apoptosis. The direct implication of this study is that combination treatment with NPRL2 and cisplatin may overcome
cisplatin resistance and enhance therapeutic efficacy.
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Introduction
NPRL2/Gene 21 (GenBank accession #AF040707), which is
1351 bp long and encodes a protein of 380 amino acid residues,
is one of the tumor suppressor genes identified in a 120-kb
homozygous deletion region on human chromosome band 3p21.3
[1,2]. The frequent and early loss of heterozygosity and the
overlapping homozygous deletions observed in the 3p21.3 region in
lung and breast cancers suggest a critical role of one or more 3p21.3
genes in the molecular pathogenesis of these cancers [1,3].
The nitrogen permease regulator 2 (NPR2) yeast gene
(GenBank accession #P39923) was identified as a novel com-
ponent involved in cell killing triggered by cisplatin. Because
disruption of NPR2 was shown to confer resistance to cisplatin, it
was believed that NPRL2 may use a similar mechanism to mediate
the cytotoxicity of anticancer drugs [4]. We recently found that the
reexpression of NPRL2 in NPRL2-negative and cisplatin-resistant
cells significantly resensitized the response of these cells to cisplatin
treatment, as evidenced by reduced cell viability and increased
apoptosis in vitro and in vivo [5]. However, the molecular events
responsible for resensitization to cisplatin by NPRL2 have not been
identified. In this study, we attempt to understand the molecular
link between NPRL2 and cisplatin in overcoming drug resistance.
The effects of cisplatin are mediated through high levels of DNA
damage, leading to programmed cell death or cell cycle arrest [6].
The double-strand DNA breaks induced by cisplatin are mediated
through a central DNA damage-signaling pathway controlled by
the ataxia telangiectasia mutated (ATM) kinase as well as several
other DNA damage-responsive kinases [7,8]. The phosphorylation
of ATM at serine-1981 has been shown to phosphorylate histone
H2AX [9], and the phosphorylation of histone H2AX at serine-
139 (c-H2AX) is essential for the recruitment of mediators such as
MDC1 (mediator of DNA damage checkpoint protein 1), 53BP1
(p53 binding protein 1), BRCA1 (breast cancer 1), and MRE11
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(Nijmegen breakage syndrome 1) complex [10–13]. Phospho-
ATM facilitates the phosphorylation of those mediators, and the
formation of nuclear foci of the activated molecules promotes
transmission of the DNA damage signal to downstream targets,
such as Chk1 (check point kinase 1), Chk2 (check point kinase 2),
and SMC1 (structural maintenance of chromosomes 1) [14–16].
Chk1 and Chk2 are involved in various DNA-damage responses,
including cell-cycle checkpoint, genome maintenance, DNA
repair, and apoptosis [17].
Therefore, we hypothesized that the sensitization of non-small
cell lung cancer (NSCLC) cells to cisplatin by NPRL2 may be due
to the direct regulation of key components in the DNA-damage
checkpoint pathway. To test this hypothesis, we analyzed effects of
the ectopic expression of NPRL2 in the presence or absence of the
DNA-damaging agent cisplatin on tumor cell growth and
apoptosis in a panel of NSCLC cell lines with varied status of
the endogenous NPRL2 gene and protein expression and cisplatin
sensitivity. We show that reexpression of NPRL2 in NPRL2-
negative and cisplatin-resistant cells significantly activates those
key components, including ATM, Chk, and H2AX, and
resensitizes lung cancer cells to cisplatin treatment in vitro and in
vivo, leading to cell cycle arrest in the G2/M phase and induction
of apoptosis. The findings of the present study also lend
experimental support to our hypothesis that NPRL2 may function
not only as a prognostic biomarker for sensitivity to cisplatin, but
also as a therapeutic agent for resensitizing nonresponding cancer
cells to cisplatin.
Materials and Methods
Cell lines and cell culture
The human NSCLC cell lines H1299 [5] and H322 [5], with
various 3p21.3 status described previously [18,19], were used for in
vitro and in vivo experiments. H1299 and H322 are cisplatin-
resistant (50% inhibitory concentration [IC50] and IC20 values for
cisplatin in H1299 were 7.6 and 3.0 mM, respectively, and in
H322 were 13.1 and 5.0 mM, respectively, as assessed by XTT
assay) and do not express NPRL2 protein (as assessed by Western
blotting) [5]. The cisplatin-sensitive NSCLC cell line H1437 and
cisplatin-resistant cell line H1437R have been described previously
[5].
Antibodies, reagents, and dosage
Anti-ATM (5C2), anti-Chk1 (G-4), anti-Chk2 (H-300), anti-
Cdc25A (F-6), anti-cyclin B1 (GNS1), and anti-caspase-2 (H-19)
were purchased from Santa Cruz Biotechnology (Santa Cruz, CA).
Anti-phospho-Chk1 (Ser345), anti-phospho-Chk2 (Thr68), anti-
phospho-Chk1 (Ser345), anti-NBS1, anti-phospho-NBS1 (Ser343),
anti-SMC1, anti-phospho-Cdc25C (Ser216), anti-phospho-Cdc2
(Tyr15), anti-caspase-3, and anti-caspase-9 were purchased from
Cell Signaling Technology (Beverly, MA). Anti-ATM Protein
Kinase pS1981 was from Rockland Immunochemicals (Gilberts-
ville, PA), anti-phospho-histone H2AX (Ser139) was from Upstate
Biotechnology (Lake Placid, NY), anti-phospho-SMC1 was from
Novus Biologicals (Littleton, CO), and anti-caspase-8 and anti-
poly (ADP-ribose) polymerase (PARP) were from BD Biosciences
Pharmingen (San Diego, CA).
For all Western blotting, anti-b-actin (Sigma, St. Louis, MO)
was used as loading control. Cisplatin was purchased from Bristol-
Myers Squibb Company (Princeton, NJ). DOTAP was used to
transfect the plasmid vectors to H1299 and H322 cells. Cisplatin
treatment was always administered to cells at the IC20 dosage (5).
DOTAP:cholesterol (DOTAP:Chol) (20 mM) in 5% dextrose in
water, used for in vivo experiments, was synthesized by our
laboratory with use of standard procedures previously described
[5].
Construction of plasmid vectors expressing NPRL2
NPRL2 cDNA was excised from the plasmid pAd-RAP-NPRL2
[2] containing human NPRL2 cDNA and was ligated into the
multicloning site of pdCpG-KGB2 expression vector. The cloning
strategy has been previously described [5]. Empty vector (pdCpG-
KGB2) and a plasmid vector expressing the LacZ gene were used
as negative controls. We had previously confirmed that the
transfection by this NPRL2 vector could indeed express exogenous
NPRL2 protein in vitro and in vivo [5] by using anti-NPRL2
antibody purchased from Abcam (Cambridge, MA).
Immunofluorescence staining and flow cytometric
analyses for c-H2AX
Immunofluorescence staining was performed in cells cultured in
chamber slides. At designated time points, H1299 cells treated
with NPRL2 with or without cisplatin were fixed in 10% formalin
and incubated with anti-phospho-histone H2AX (Ser139) (1:100)
antibodies in 5% phosphate-buffered saline (PBS) with bovine
serum albumin for 1 h at room temperature. Subsequently, the
cells were incubated with donkey anti-mouse IgG-fluorescein
isothiocyanate (FITC) (Santa Cruz Biotechnology) diluted 1:100 in
PBS for 45 min, and the samples were mounted with VECTA-
SHIELD mounting medium with 49,6-diamidino-2-phenylindole
(DAPI) (Vector Laboratories Inc., Burlingame, CA) to counter-
stain the nuclei. Immediately, the slides were examined with use of
a fluorescence microscope. Also, after incubation of the FITC
antibody, the cells were harvested, and FITC-positive cells were
counted by flow cytometric analysis.
Chk1 and Chk2 kinase activity assay
Chk1 and Chk2 kinase activity in H1299 cells treated with
NPRL2 with or without an IC20 value of cisplatin were assessed
with use of a K-LISA Checkpoint Activity Kit (EMD Biosciences,
San Diego, CA), which is an enzyme-linked immunosorbent assay
(ELISA)-based activity assay. Briefly, H1299 cells were plated in
60-mm dishes at 4610
5 cells per dish and the following day were
treated with 4 mg of empty vector or NPRL2 with or without
3.0 mM cisplatin. After 72 h of incubation, cell lysates were
prepared by using radioimmunoprecipitation assay (RIPA)/PBS
buffer (1% NP-40, 0.5% sodium deoxycholate, 0.1% sodium
dodecyl sulfate [SDS]). Cell lysates (0.5 ml with total protein
concentration of 2 mg/ml) were pre-cleared by adding 15 mlo f
Protein A/Protein G-Plus agarose beads (Santa Cruz Biotechnol-
ogy) and incubated for 15 min at 4uC. After centrifugation, the
pre-cleared lysates were transferred to a fresh tube with 20 mlo f
Chk1 or Chk2 antibody and rotated for 1 h at 4uC. Next, 50 mlo f
protein A/protein G-Plus agarose beads were added and rotated
for 90 min at 4uC. The agarose beads were washed with RIPA/
PBS buffer, and a K-LISA Checkpoint Activity Kit was used
according to the manufacturer’s instructions. Activity was
determined by reading the absorbance at dual wavelengths of
450 and 570 nm with use of a conventional ELISA plate reader.
Generation of stable clones of lung cancer cell lines with
short interfering RNA-mediated Chk2 gene silencing
To generate cell lines with stable knockdown of Chk2
expression, we initially screened four short interfering RNAs
(siRNAs) cloned into double (U6-H1) promoter expression vectors
purchased from System Biosciences (Mountain View, CA). Briefly,
NPRL2, Lung Cancer & CDDP
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Chk2 siRNA designed based on web-based tools. All sense oligos
had AAAG at the 59 end, and all antisense oligos had AAAA
sequence at the 59 end. We also included a mutant as control.
The sequences were as follows: CHK2Si1:59aaagGAACCTGAG-
GACCAAG39; CHK2ASi1:59aaaaCTTGGTCC TCAGGTT-
C39; CHK2Si2:59aaagCGCCGTCCTTTGAATA 39; CHK2A-
Si2:59aaaaTATTC AAAGGACGGCG39; CHK2Si3:59aaagAA-
CGGTATTATACAC CHK2ASi3:59aaaaGTG TATAATACC-
GTT 39; CHK2Si4:59aaagAGTTTCAAGATCTTCTGTC 39;
CHK2ASi4:59a aaaGACAGAAGATCTTGAAACT 39; CHK2-
Simta:59aaagGCTAGCTAGTCGATC 39; CHK2Simtb:59aaaa-
GATCGACTAGCTAGC39. Stable clones were selected with use
of puromycin (1 mg/ml); and after they were established, they were
screened for expression levels of Chk2 protein relative to control.
The clone with the best silencing effect (CHK2Si1 and
CHK2ASi1) was chosen for the functional studies.
Transient silencing of NPRL2 gene expression in lung
cancer cell lines. For transient knockdown of NPRL2
expression, we used synthetic double stranded siRNAs to target
the NPRL2 coding mRNA sequence and the corresponding
scrambled siRNAs were used as non-specific controls. A SMART-
pool of four On-target NPRL2-specific siRNAs were used for this
study: the target sequences were 59GCAUCGAACACAAG-
AAGUA 39,5 9GCAAGACAGGCAUGAGCUA 39,5 9GUACU-
ACGGCGUUGUGACA 39, and 59GAC CCAAGAUCACCU-
AUCA 39. These siRNAs were purchased from Dharmacon
(Lafayette, CO). H1299 cells were co-transfected with NPRL2
expressing plasmid and NPRL2-siRNAs, and empty plasmid
vector and scrambled siRNAs were used as controls, respectively.
Cells were first transfected with NPRL2 plasmid vector using
FUGENE 6 (Roche, Indianapolis, IN) with 2.5 mg of DNA for
2610
5 cells per well in a 6-well plate. Six hours after plasmid
transfection, the cell culture medium was replaced with fresh one
without antibiotics and cells were then transfected with siRNAs
using DharmaFECT transfection reagent with 50 mM of SiRNA
complexed with 5 ml of DharmaFECTper well in the above 6-well
plate. Cells were collected 24, 48, and 72 hours after transfection
for preparation of crude protein lysates for Western blot analysis.
Immunoprecipitation-Western blot analyses
H1299 cells were treated with 4 mg of empty vector or NPRL2
with or without 3.0 mM cisplatin. After 72 h of incubation, cell
lysates were prepared by using RIPA/PBS buffer (1% NP-40,
0.5% sodium deoxycholate, 0.1% SDS). After blocking with 1 mg
of normal IgG and 20 ml of protein A/protein G-Plus agarose
beads (Santa Cruz Biotechnology), protein was immunoprecipi-
tated from 500 mg extracts by using 2 mg of anti-Cdc2 or anti-
cyclin B1 antibody (Santa Cruz Biotechnology) and 30 mlo f
protein A/protein G-Plus agarose beads for 5 h at 4uC. The
agarose was collected by centrifugation and then washed four
times with ice-cold PBS buffer. Next, the immunoprecipitates were
resuspended in 16 SDS sample buffer and heated with 50 mM
DTT at 95uC for 5 min; Western blotting was performed as
described previously [20].
Analysis of cell cycle kinetics
Changes in cell cycle kinetics in tumor cells treated with NPRL2
with or without cisplatin were analyzed by flow cytometry (with
use of a fluorescence-activated cell sorter [FACS]) using an APO-
BRDU KIT (BD Biosciences Pharmingen). Briefly, cells were
plated in 60-mm dishes at 4610
5 cells per dish; the following day,
the cells were treated with 4 mg of empty vector or NPRL2-
expressing vector with or without cisplatin. At designated time
points, cells were harvested and fixed in 1% paraformaldehyde.
After incorporation of 5-bromo-29-deoxyuridine 59-triphosphates
(BrdUTPs), cells were visualized with use of FITC-labeled anti-
BrdU antibody. The amount of total cellular DNA was obtained
by staining cells with PI/RNase buffer. Cells were processed for
FACS analysis by terminal deoxynucleotidyltransferase-mediated
deoxyuridine 5-triphosphate (dUTP) nick-end labeling (TUNEL
staining) to determine cell cycle kinetics, as described previously
[20].
Animal studies
All animals were maintained and experiments performed
according to National Institutes of Health and institutional
guidelines established for the Animal Core Facility at The
University of Texas M. D. Anderson Cancer Center. The animals
used in this study were female Nu/nu mice (4–6 weeks of age) that
were purchased from Charles River Laboratories (Wilmington,
MA). Before tumor cell inoculation, mice were subjected to 3.5
Gy of total body irradiation from a cesium-137 radiation source
to completely render the immune system of nude mice from
rejection of tumor xenografting. To evaluate the efficacy of
systemic administration of NPRL2 and cisplatin in an orthotopic
model of pleural dissemination, the mice received an intratho-
racic injection (27-gauge needle) of a suspension of H322 cells at
a density of 2610
6 cells per 100 ml. The mice were randomly
divided into the following 4 groups: A, treated with LacZ; B,
treated with LacZ and cisplatin; C, treated with NPRL2; and D,
treated with NPRL2 and cisplatin. Each treatment group
consisted of 2 mice.
On day 26, we administered various nanoparticles (DOTAP:-
Chol-DNA complex) intravenously in tail veins of all mice at a
dose of 25 mg of plasmid DNA (LacZ or NPRL2 plasmid) and 10
nmol of DOTAP:Chol each in 100 ml of 5% dextrose in water
per mouse. In groups B and D, we injected cisplatin (2.5 mg/kg
body weight) intraperitoneally along with the nanoparticles. To
estimate c-H2AX and phospho-Chk2 (Thr68) expression in
tumors, the mice were sscrificed 48 h later, and the pleural
tumors (larger than 5 mm) of each group were randomly
harvested and flash frozen. c-H2AX expression was estimated
by anti-phospho-histone H2AX (Ser139) (1:100) antibody and
donkey anti-mouse IgG-FITC. The samples were then mounted
with VECTASHIELD with DAPI to counterstain the nuclei.
Immediately, the slides were examined with use of a fluorescence
microscope. Also, phospho-Chk2 expression was analyzed by
anti-phospho-Chk2 (Thr68) antibody (1:100) by using a VEC-
TASTAIN Elite ABC kit (Vector Laboratories) and was then
microscopically examined.
Statistical analyses
All experiments were repeated at least two times with duplicate
or triplicate samples. ANOVA and Fisher’s test were used to
compare the values of the test and control samples. P,0.05
was considered statistically significant. StatView 5.0 software
(Abacus Concepts, Inc., Berkeley, CA) was used for all statistical
analyses.
Results
Induction of caspase activities in response to treatment
with NPRL2 and cisplatin
NPRL2 sensitizes cisplatin-resistant cells (H1437R) to cisplat-
in-induced apoptosis (Figure 1A). Increased apoptosis was
detected in all three NPRL2-negative, cisplatin-resistant cell
lines treated with forced expression of NPRL2 and cisplatin. As
NPRL2, Lung Cancer & CDDP
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and 21.8% of H1437R, H1299, and H322 cells, respectively,
after combined treatments. We also used Western blotting to
determine the activation of caspases in H1299 cells treated with
empty vector, empty vector plus cisplatin, NPRL2, or NPRL2
plus cisplatin (Figure 1B). Caspase-3, -8, and -9 were activated
only in H1299 cells treated with NPRL2 and cisplatin, as shown
by the cleavage products. Activation of caspase-2 was detected in
cells treated with cisplatin or NPRL2 alone as well as the
combination.
Figure 1. Induction of caspases by exogenous expression of NPRL2 and cisplatin in non-small cell lung cancer cells. (A) Induction of
apoptosis in H1299 cells treated NPRL2 in the presence or absence of cisplatin (CDDP) by flow cytometry analysis with TUNEL staining. The PBS
treated and empty vector (EV) treated cells were used as mock and negative controls, respectively. Error bars indicate SDs of the mean in three
individual experiments (*, P,0.05; **, P,0.0005). (B), Activation of caspase cascades in H1299 cells by Western blot analysis. Several caspases in
H1299 cells were examined by Western blotting 72 h after treatment with empty vector (EV) (with or without cisplatin) or with NPRL2 (with or
without cisplatin). In cells treated with NPRL2 and cisplatin, caspases-3, -2, -8, and -9 and poly (ADP-ribose) polymerase (PARP) were cleaved. Also,
caspase-2 was activated by treatment with only NPRL2.
doi:10.1371/journal.pone.0011994.g001
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We used Western blotting analysis to evaluate the activation of
ATM in H1299 cells in response to ectopic activation of NPRL2 in
the presence or absence of cisplatin (Figure 2A). In H1299 cells
transfected with NPRL2, we detected a low level of phosphor-
ATM (Ser1981) that had been activated by ATM kinase; after
treatment with NPRL2 and cisplatin, the phosphor-ATM level
markedly increased in a time-dependent manner. In H1299 cells
treated with empty vector control and cisplatin, we detected no
change in phosphor-ATM expression compared with the untreat-
ed control. We also examined the expression of phospho-NBS1
(Ser343) (Figure 2A), which is phosphorylated by activated ATM
and recruited to sites of DNA damage to promote transmission of
a series of DNA damage signals to downstream targets. Although
phospho-NBS1 was not detected in H1299 cells treated with
empty vector and cisplatin, it was detected in H1299 cells treated
with NPRL2, and substantially increased in a time-dependent
manner after treatment with NPRL2 and cisplatin.
The specificity of the NPRL2-mediated activation of the ATM
signaling pathway was further confirmed by experiments using
gene-specific siRNAs to knockdown NPRL2 expression in the
presence and absence of cisplatin in these H1299 cells (Figure 2B).
Ectopic activation of NPRL2 in NPRL2-deficient H1299 cells
activated ATM, as indicated by the upregulated phospho-ATM
expression at 24 h and 48 h post transfection in both the presence
and absence of cisplatin. Knockdown of NPRL2 expression by
NPRL2-specific siRNAs reduced or diminished the NPRL2-
mediated upregulation of phospho-ATM expression, compared to
those treated scrambled siRNAs controls at the same time points.
NPRL2 enhances expression of cH2AX in vitro and in vivo
We used Western blotting for a time course evaluation of c-
H2AX protein expression (Figure 3A). In H1299 cells treated
with empty vector and cisplatin or NPRL2, c-H2AX protein levels
increased and were the same by 24 and 48 h after treatment.
However, by 72 h, the c-H2AX protein levels in cells treated with
empty vector and cisplatin decreased markedly, whereas levels in
cells treated with NPRL2 remained almost the same as those at the
24-h and 48-h time-points. In cells treated with a combination of
NPRL2 and cisplatin, c-H2AX protein levels increased in a time-
dependent manner.
Next, immunofluorescence staining and flow cytometric analysis
for c-H2AX expression at 48 h after treatment was performed
(Figure 3B). Expression of c-H2AX protein expression in the
nuclei of cells treated with both NPRL2 and cisplatin was
enhanced compared with that in all other groups. Furthermore,
the mean FITC intensity of NPRL2 and cisplatin treatment was
significantly elevated compared with that of all other treatments
(P,0.02) during the time course.
c-H2AX protein expression was then measured in a human
NSCLC H322 orthotopic pleural tumor xenograft in mice. The
H322 cell line is NPRL2-negative and cisplatin-resistant. On day
26 after intrathoracic injection of H322 cells, we administered
NPRL2 or LacZ nanoparticles in the tail vein with or without
Figure 2. Activation of ATM signaling pathway by ectopic expression of NPRL2 protein. (A), Effects of ectopic expression of NPRL2 on
expression and phosphorylation of ATM and NBS1 proteins.H1229 cells treated with an empty vector (EV) vector and IC20 dose of cisplatin (3.0 mM),
NPRL2, or NPRL2 and IC20 dose of cisplatin were harvested at 24, 48, and 72 h after treatment and analyzed for expression of ataxia telangiectasia
mutated (ATM) kinase, phospho-ATM (Ser1981), NBS1, and phospho-NBS1 (Ser343). b-actin was used as a loading control. Increases in phospho-ATM
and phospho-NBS1 were observed in cells treated with NPRL2 or NPRL2 and cisplatin in a time-dependent manner, but not in cells treated with the
control empty vector and cisplatin. (B), Effects of NPRL2-specific siRNA (Si) on expression of NPRL2 and ATM proteins in the presence and absence of
cisplatin (CDDP). The scrambled siRNA (Sc) was used as a non-specific control.
doi:10.1371/journal.pone.0011994.g002
NPRL2, Lung Cancer & CDDP
PLoS ONE | www.plosone.org 5 August 2010 | Volume 5 | Issue 8 | e11994Figure 3. c-H2AX, induced by cisplatin treatment, is also strongly enhanced by NPRL2. H1229 cells treated with an empty vector and IC20
dose of cisplatin (3.0 mM), NPRL2, or NPRL2 and IC20 dose of cisplatin were harvested at 24, 48, and 72 h after treatment. (A) Western blot shows
remarkably enhanced expression of c-H2AX in cells treated with NPRL2 and cisplatin compared with cells treated with empty vector and cisplatin. (B)
c-H2AX expression was examined at 48 h after treatment by immunofluorescence staining and flow cytometric analysis. c-H2AX expression was
detected in cells treated with empty vector and cisplatin or NPRL2 but not in cells treated with empty vector only, and this expression was
dramatically enhanced in cells treated with NPRL2 and cisplatin. Magnification: 6800. Mean fluorescein isothiocyanate (FITC) intensity was also
examined at 24, 48, and 72 h after treatment. At these three time points, c-H2AX expression in cells treated with NPRL2 and cisplatin was significantly
higher than that in cells in all other treatments (P,0.02 or P,0.0005). Bars, SDs of the mean in two individual experiments. (C) c-H2AX expression was
analyzed by immunofluorescence staining in an orthotopic model of H322 pleural dissemination, as described in the Materials and Methods section.
The pleural tumor cells from the mice treated with LacZ and cisplatin or NPRL2 were weakly stained; in contrast, c-H2AX was hyperexpressed in cells
treated with NPRL2+ cisplatin. Magnification: 6400.
doi:10.1371/journal.pone.0011994.g003
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and IC20 of cisplatin (3.0 mM), NPRL2, or NPRL2+ with IC20 dose of cisplatin were harvested at 24, 48, and 72 h after treatment and analyzed for
expression of Chk1, P-Chk1 (Ser345), Chk2, and P-Chk2 (Thr68). In cells treated with empty vector and IC20 dose of cisplatin or NPRL2, P-Chk1
increased in a time-dependent manner. In contrast, in those treated with NPRL2 and IC20 dose of cisplatin, P-Chk1 was dramatically enhanced.
Although P-Chk2 was not detected in H1299 cells treated with empty vector and IC20 dose of cisplatin, it was clearly increased in a time-dependent
manner in those treated with NPRL2 or NPRL2+ IC20 dose of cisplatin. (B) P-Chk2 expression was immunohistochemically analyzed in an orthotopic
model of H322 pleural dissemination, as described in the Materials and Methods section. P-Chk2 expression was slightly detected in pleural tumor
cells from mice treated with NPRL2 nanoparticles, but not in those treated with LacZ or LacZ + cisplatin. In contrast, treatment by NPRL2
nanoparticles and cisplatin induced high phospho-Chk2 expression in tumor cells. Magnification: 6400. (C) The kinase activity of Chk1 and Chk2 in
H1299 cells treated with empty vector + IC20 dose of cisplatin, NPRL2 or NPRL2+ IC20 dose of cisplatin was analyzed with use of a K-LISA Checkpoint
Activity Kit, an enzyme-linked immunosorbent assay (ELISA)-based activity assay. Chk1 kinase activity was greater in cells treated with NPRL2+
cisplatin than in cells treated with empty vector or empty vector + cisplatin (P,0.003). Chk2 kinase activity was more strongly enhanced in cells
treated with NPRL2 or NPRL2+ cisplatin than in cells treated with empty vector or empty vector + cisplatin (P,0.0001). Bars, SDs of the mean in four
individual experiments.
doi:10.1371/journal.pone.0011994.g004
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mice treated with LacZ along with cisplatin or NPRL2 weakly
stained for c-H2AX (Figure 3C). Tumors treated with NPRL2
and cisplatin showed high levels of c-H2AX (Figure 3C).
Activation of Chk1 and Chk2 by NPRL2 and cisplatin in
vitro and in vivo
We examined the phosphorylation of Chk1 on Ser-345 and
Chk2 on Thr-68 by Western blotting (Figure 4A). In H1299 cells
treated with empty vector and cisplatin or NPRL2, phosphory-
lated Chk1 increased in a time-dependent manner. In cells treated
with NPRL2 and cisplatin, Chk1 expression was greatly enhanced.
Although phosphorylated Chk2 was not detected in H1299 cells
treated with empty vector and cisplatin, it clearly increased in a
time-dependent manner in cells treated with NPRL2 or NPRL2
with cisplatin. We evaluated phospho-Chk2 protein expression in
the orthotopic tumor xenografts by immunohistochemical staining
of tumor cells from each group (Figure 4B). The tumor cells from
the mice treated with LacZ or LacZ and cisplatin had very low-
level staining. For tumors treated with NPRL2, phospho-Chk2
expression was detected at a low level (Figure 4B). Treatment
with combination NPRL2 and cisplatin induced high phospho-
Chk2 expression.
We also measured the kinase activity of Chk2 and Chk1 in
H1299 cells treated with NPRL2 with or without cisplatin with use
of the K-LISA Checkpoint Activity Kit, an ELISA-based kinase
activity assay. Chk2 kinase activity in cells treated with NPRL2 or
NPRL2 and cisplatin was strongly enhanced compared with
activity in cells treated with empty vector with or without cisplatin
(P,0.0001) (Figure 4C). Chk1 kinase activity in cells treated with
NPRL2 and cisplatin was stronger than in cells treated with empty
vector with or without cisplatin (P,0.003) (Figure 4C).
To further define the nature of Chk2 interaction with NPRL2,
we analyzed the effect of NPRL2 and Chk2 expression on
apoptosis by using Chk2-specific siRNA (Figure 5A) to knock
down Chk2 expression in cisplatin-resistant H1437 cells (H1437R)
(Figure 5B). The level of apoptosis was determined by FACS
analysis with terminal deoxynucleotidyltransferase-mediated deox-
yuridine 5-triphosphate (dUTP) nick-end labeling (TUNEL)
staining. The down-regulated Chk2 expression attenuated
NPRL-2-induced apoptosis and its ability to sensitize the tumor
cells’ response to cisplatin.
Enhanced effect of cisplatin in activating cell cycle
checkpoints and fostering G2 arrest by NPRL2
To study the effect of NPRL2 on cell cycle kinetics, we
examined the expression of Cdc25A, phospho-Cdc25C (Ser-216),
phospho-Cdc2 (Tyr-15), and phospho-SMC1 (Ser-957) by West-
ern blotting (Figure 6A). Cdc25A expression was reduced after
treatment with NPRL2 or cisplatin at 72 h after treatment, but
this reduction occurred at 24 h with combination treatment.
Although phospho-Cdc25C expression was slightly increased by
cisplatin, it was markedly increased after treatment with NPRL2
or NPRL2 and cisplatin. Moreover, expression of both phospho-
Cdc2 and phospho-SMC1 increased more after treatment with
NPRL2 and cisplatin than after treatment with either cisplatin or
NPRL2. We examined whether NPRL2 influences the interaction
of the Cdc2/cyclin B1 complex by using immunoprecipitation
(Figure 6B). NPRL2 and cisplatin treatment reduced the binding
of Cdc2 and cyclin B1 more effectively than did all other
treatments.
Next, the cell cycle in tumor cells treated with NPRL2 and
cisplatin was analyzed by flow cytometry (FACS) with use of a
APO-BRDU KIT (Figure 7A). The shift in cell cycle kinetics of
cells treated with NPRL2 was manifested as clear G1 and G2
peaks at 72 h after treatment, consistent with the cells accumu-
lating at the G1-S and G2-M checkpoints in response to
inactivation of Cdc25A and Cdc25C by NPRL2 (Figure 7A).
In contrast, the cell cycle distribution showed an increase in the
G2/M population after treatment with cisplatin, compared with
cells treated with NPRL2 alone. The combination of NPRL2 and
cisplatin, however, increased the G2/M population more than
either NPRL2 or cisplatin alone did, and in a time-dependent
manner (P,0.001) (Figure 7B). In addition, the combination
treatment increased the sub-G0-G1 population more than all
other treatments did (P,0.001), and in a time-dependent manner
(Figure 7B).
Discussion
In this study, we showed that exogenous NPRL2 expression in
NPRL2-negative tumor cells activated the DNA damage pathway,
as evidenced by activation of ATM and NBS1 and increased c-
H2AX expression in lung cancer cells after NPRL2 treatment.
NPRL2 treatment resulted in accumulation of cells at the G1-S
and G2-M checkpoints associated with inactivation of Cdc25A
and Cdc25C and degradation of the cyclin-Cdk complex.
Treatment with only NPRL2 induced strong activation and
cleavage of caspase-2, suggesting that the activation of caspase-2
may be one of the early NPRL2-mediated molecular events.
Caspase-2 is required to translocate Bax protein to the
mitochondria, permeabilize the mitochondrial membrane, and
release apoptogenic factors such as cytochrome C from these
organelles [21,22]. These results indicate that the essential
function of exogenous NPRL2 involves the activation of the
DNA damage checkpoint pathway, which regulates not only cell
Figure 5. Lung cancer cell line H1437R was used to analyze
apoptosis by flow cytometry after treatment with NPRL2 and
IC20 dose of cisplatin. (A) Western blot shows reduction in Chk2
expression using SiRNA specific to Chk2 (SiChk2) and scrambled siRNA
(SiScrb) as control in stable clones generated in 1437R lung cancer cell
line. (B) Measurement of cellular apoptosis by fluorescence-activated
cell sorter (FACS) analysis with TUNEL staining. Results show that down-
regulated Chk2 expression attenuated NPRL-2-induced apoptosis and
its ability to sensitize tumor cells’ response to cisplatin.
doi:10.1371/journal.pone.0011994.g005
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senescence, and apoptosis [17].
One potentially important means by which DNA adducts
caused by cisplatin may kill cells is by induction of programmed
cell death or apoptosis [23]. It is generally accepted that the main
mechanisms affecting the occurrence of cisplatin resistance include
increased drug efflux, decreased drug influx, increased cellular
glutathione and metallothionein levels, increased DNA repair, and
oncogene expression [24]. However, emerging evidence suggests
that a significant number of cases of cisplatin resistance might be
the result of a defective apoptotic program. In such cases,
increased levels of DNA damage would be required to induce
signal-initiating apoptosis [25]. Indeed, we demonstrated that after
cisplatin treatment, phosphorylated ATM and NBS1 were
expressed at very low levels.
Phosphorylation of histone H2AX by activated ATM, referred
to as c-H2AX, is dispensable for the initial recognition of DNA
damage and recruitment of the mediators of the DNA damage
checkpoint, including specific DNA-repair complexes, to the site of
DNA damage [10,12,13,26]. Cells from mice that lack the H2AX
gene manifest a G2/M checkpoint defect similar to that in ATM-
deficient cells exposed to low doses of ionizing radiation (12). c-
H2AX appears during apoptosis concurrently with the initial
appearance of high-molecular-weight DNA fragments. Therefore,
c-H2AX formation is an early chromatin modification event that
follows initiation of DNA fragmentation during apoptosis before
DNA repair [27].
Adding exogenous NPRL2 to cisplatin treatment induces three
key events in the DNA damage pathway. First, this combination
increases c-H2AX expression compared with cisplatin-only
treatment. It has been reported that c-H2AX formation is induced
by apoptotic DNA fragmentation, a critical event that occurs
during apoptosis. Electroporation of DNase I or restriction
enzymes into cells is sufficient to induce the formation of c-
H2AX, suggesting that mere activation of diverse apoptotic
nucleases should generally result in c-H2AX formation [27].
Furthermore, it was reported that c-H2AX formation is a cellular
response to endonuclease-mediated DNA fragmentation down-
stream of caspases in the course of apoptosis [27]. Gamma-H2AX
hyperphosphorylation is strongly correlated to apoptotic chroma-
tin fragmentation, and this phosphorylation in apoptotic cells
depends indirectly on activation of caspases and nuclear scaffold
Figure 6. NPRL2 enhances the effect of cisplatin that can activate cell cycle checkpoints. H1229 cells treated with empty vector + IC20
dose of cisplatin (3.0 mM), NPRL2, or NPRL2+ IC20 dose of cisplatin were harvested at 24, 48, and 72 h after treatment and analyzed by Western
blotting for expression of cell cycle signaling molecules. Control H1299 cells were treated with empty vector and harvested at 72 h after treatment. b-
actin was used as a loading control. (A) Cdc25A was degraded by the treatment of NPRL2 or IC20 dose of cisplatin 72 h later, and this degradation in
treatment of NPRL2+ cisplatin strongly appeared 24 to 72 h later. P-Cdc25C was slightly increased by treatment with cisplatin; in contrast, it was
remarkably increased by treatment with NPRL2 or NPRL2+ cisplatin. P-Cdc2 and P-SMC1 were clearly enhanced more with NPRL2+ cisplatin treatment
than with cisplatin or NPRL2 treatment. (B) Immunoprecipitation Western blotting (IP-WB) analysis for protein-protein interaction between Cdc2-
cyclin B1. H1299 cells were transfected with either empty vector or NPRL2 plasmid with or without IC20 value of cisplatin. The backbone plasmid
vector without NPRL2 was used as a transfection control. Protein extracts were collected 72 h after transfection and immunoprecipitated with either
anti-Cdc2 or anti-cyclin B1 antibody and immunoblotted with Cdc2 or cyclin B1 antibody. NPRL2 and cisplatin treatment remarkably degraded the
interaction of Cdc2/cyclin B1 complex.
doi:10.1371/journal.pone.0011994.g006
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activated and PARP is cleaved only in NPRL2 and cisplatin
combination treatment. Also, PARP was cleaved in cells treated
with exogenous NPRL2 and cisplatin, suggesting that treatment of
NPRL2 and cisplatin enhances c-H2AX expression and induces
strong apoptosis.
Second, adding NPRL2 treatment to cisplatin significantly
enhances Chk1 and Chk2 kinase activity. We were able to detect
phospho-Chk2 expression in metastatic tumors in an orthotopic
model, even though it was not detected after treatments with only
cisplatin.
Third, the combination of NPRL2 and cisplatin increased the
G2/M population in a time-dependent manner compared with
treatment of cisplatin only.
The activation of Chk1 and Chk2 after DNA damage is
dependent on the activated ATM or ATR protein kinase [29].
Chk2 is phosphorylated on Thr-68, which thereby promotes the
oligomerization of Chk2 by creating a specific binding site for the
FHA domain of another Chk2 molecule. The homodimerization
of Chk2 also facilitates transphosphorylation of the C-terminal
kinase domain (Thr-383, Thr-387), which is required for full
activation of Chk2 [30,31]. In contrast, Chk1 is activated by
phosphorylation on Ser-317 and Ser-345 [32]. Activated Chk1
and Chk2 can regulate cell cycle arrest in late G1, intra S, and G2
phases through phosphorylation of substrates such as Cdc25A and
Cdc25C [33,34–38]. Furthermore, activated Chk2 can regulate
not only p53-mediated apoptosis, but also p53-independent
apoptosis [38].
The family members of Cdc25 such as Cdc25A and Cdc25C
promote cell cycle progression by activation of the cyclin-
dependent kinase Cdk2 and Cdc2 (Cdk1) through dephosphor-
ylation of inhibitory phosphorylation at Thr14 and Tyr15
[33,39,40]. Degradation of Cdc25A, resulting from phosphory-
lation by the activated Chk2 and/or Chk1, leads to sustained
inhibitory phosphorylation of Cdk2 and Cdk1 and cannot
activate the Cdk2/cyclin E or Cdc2/cyclin B complex, leading
to apparent p53-independent late G1 arrest [41], an S-phase
delay [42], or G2 arrest [36]. Phosphorylation of Ser-216 on
Cdc25C by activated Chk1 and/or Chk2 creates a binding site
for 14-3-3 protein, and this interaction is believed to result in
persistent cytoplasmic Cdc25C localization, thus preventing the
G2/M transition since the Cdc2/cyclin B complex cannot be
activated [33,43,44]. SMC1 is phosphorylated on Ser-957 and
Ser-966 by activated ATM in an NBS1-dependent manner, and
this phosphorylation of SMC1 is required for activation of the
intra-S checkpoint [16]. The intra-S checkpoint is regulated by
two parallel pathways mediated by ATM-NBS1-SMC-1 and
ATM/ATR-Chk1/Chk2-Cdc25A [42]. Combination treatment
of NPRL2 and cisplatin strongly inactivates Cdc25A and
Cdc25C. Also, phospho-Cdc2 (Tyr-15), which is an inactivated
Figure 7. Combination treatment of NPRL2 and cisplatin induces strong cell arrest in G2/M phase. The cell cycle in tumor cells treated
with NPRL2 and IC20 value of cisplatin was analyzed by flow cytometry with use of the APO-BRDU KIT. (A) The shift in cell cycle parameters of cells
treated with NPRL2 is manifested as clear G1 and G2 peaks 72 h after treatment. In contrast, the cell cycle distribution showed an increase in the G2/
M population after treatment with empty vector and cisplatin compared with cells treated with NPRL2 alone. The shift in cell cycle distribution was
seen in cells treated with NPRL2+ cisplatin: the G2/M phase population strongly increased, whereas the G1 phase population decreased. (B) The cell
cycle shift was analyzed at 24, 48, and 72 h after treatment. The combination of NPRL2 and cisplatin significantly increased the G2/M population in a
time-dependent manner (P,0.001 at 48 h; P,0.0001 at 72 h) and increased the sub-G0-G1 population (P,0.001 at 72 h), compared with all other
treatments. Bars, SDs of the mean from three individual experiments.
doi:10.1371/journal.pone.0011994.g007
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treatment but not with cisplatin treatment only.
Moreover, we found that with immunoprecipitation of Cdc2
and cyclin B1, combination NPRL2 and cisplatin treatments
degraded the interaction of Cdc2 and cyclin B1, leading to
inactivation of the Cdc2/cyclin B1 complex and arrest in G2/M.
Proliferating cells treated with cisplatin arrest in G2/M [45,46].
Cisplatin-induced apoptosis is dependent on the presence of cells
in the S and G2/M phases of the cell cycle, even in a cell type that
seemed ‘‘primed’’ for the induction of apoptosis [47]. Also, we
previously reported that lung cancer cells arrested at the G2/M
phase ultimately underwent apoptosis with characteristic nuclear
fragmentation [48].
Therefore, we hypothesize that combining NPRL2 with
cisplatin can enhance the induction of apoptosis that essentially
prevents the potentially dangerous passage of damaged cells into
mitosis. Indeed, apoptotic cells increased 2- to 3-fold in cisplatin-
resistant and NPRL2-negative cells transfected with NPRL2
compared with those treated with cisplatin alone. Moreover,
tumor cells treated with NPRL2 and cisplatin have a remarkably
high number of TUNEL-positive cells compared with those
treated with cisplatin alone in an orthotopic model of cisplatin-
resistant pleural dissemination (5).
The cell cycle in tumor cells treated with NPRL2 and cisplatin
was analyzed by flow cytometry (FACS). The shift in cell cycle
kinetics in cells treated with NPRL2 was manifested as clear G1
and G2 peaks at 72 h after treatment, consistent with the cells
accumulating at the G1-S and G2-M checkpoints in response to
the inactivation of Cdc25A and Cdc25C by NPRL2. In contrast,
the cell cycle distribution showed an increase in the G2/M
population after treatment with cisplatin, compared with cells
treated with NPRL2 alone. It was reported that cisplatin-treated
cells arrested in G2 in an attempt to repair cisplatin-induced DNA
damage before passage into mitosis [49]. If cisplatin-induced
cellular damage were irreparable during the G2 phase, controlled
elimination of platinated cells via apoptosis would prevent the
passage of these cells into mitosis [23,50]. Therefore, it is
interesting that the combination of NPRL2 and cisplatin increases
the G2/M population in a time-dependent manner, suggesting
that NPRL2 can enhance the induction of apoptosis, a potentially
important process by which cisplatin-DNA adducts kill cells. In
addition, this combination treatment increased the sub-G0-G1
population more than all other treatments did, and in a time-
dependent manner.In summary, we hypothesize that NPRL2
activates the DNA damage checkpoint pathway in cisplatin-
resistant and NPRL2-negative cells. The combination of NPRL2
and cisplatin can enhance and resensitize the response of cisplatin-
nonresponders to cisplatin treatment through the strong activation
of the DNA damage checkpoint pathway, leading to cell cycle
arrest in the G2/M phase and induction of apoptosis (Figure 8)
and suggesting that NPRL2 gene delivery for cisplatin-resistant
patients may safely enhance the efficacy of cisplatin in the
treatment of lung cancer.
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